Obes Res Clin Pract 19:6369 Jastreboff AM, Kaplan LM, Fras JP et al (2023) Triple-hormone-receptor agonist Retatrutide for obesity - a phase 2 trial
Mozaffarian reports research funding from the National Institutes of Health, Kaiser Permanente Fund at the East Bay Community Foundation, National Association of Chain Drug Stores Foundation, Google Health, and The Rockefeller Foundation
When patients combine the right medical interventions with nutrition, movement, stress management, and sleep optimization, the results can be truly life-changing. Ready to take control of your health journey
Never shake a reconstituted peptide vial
I also think its a superfluous argument (my opinion) and muddies what I hoped the central core of the debate would bethe Carbohydrate-Insulin Model (CIM) of obesity